Providing long-acting (LA) antiretroviral therapy (ART) to breastfeeding women with HIV who face adherence challenges may be ...

Efavirenz, an HIV drug, shows potential for treating chikungunya virus, inhibiting replication and reducing viral load ...

When it came to innovations in biotech, there was a clear winner: lenacapavir, a drug that was found to prevent HIV infections in 100% of the women and girls who received it in a clinical trial.

Data from a very early-phase trial shows that the drug is safe and remains in the body for up to 56 weeks. From two ...

A new method is developed to track dormant HIV-infected cells. This breakthrough may lead to new treatments that eliminate ...

HIV prevention has advanced with lenacapavir, a yearly injection that blocks the virus's replication, providing long-term ...

Two more people have been potentially cured of HIV after receiving stem cell transplants to treat blood cancer or bone marrow ...

HIV/AIDS continues to disproportionately affect Black Americans, despite overall progress in reducing infection rates.

An annual shot to protect against HIV infection has successfully passed an early safety trial, according to research ...

New real-world and implementation study data highlight the efficacy of ViiV’s long-acting injectables for HIV prevention and ...

Every year, my colleagues and I put together a list of what we think are the top 10 breakthrough technologies of that year.

Bay Area drug giant Gilead is plotting the trial of a groundbreaking, once-a-year HIV prevention drug lenacapavir.